Report workspace

Add to folder
NCT03782454UNKNOWNanonymous

Quantification of Bacterial DNA in Septic Intensive Care Patients in Relation to Concentration of Antibiotics and Clinical Outcome: A Prospective Observation Study

Sponsor

Source record

Region Örebro County

Phase

Source record

Observational Study

Modality

AI-normalized

RNA therapy

Target

AI-normalized

Bacterial DNA clearance measured with droplet digital Polymerase Chain Reaction (ddPCR) as a biomarker for bacterial load in septic patients.

Indication / condition

AI-normalized

Septic Shock

Intervention

Source record

Blood sampling

Source & freshness

Source record

NCT ID

NCT03782454

Original source

ClinicalTrials.gov

Source last updated

Jan 29, 2019

Ingested at

Jun 17, 2026

Internal sync

Jun 17, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03782454

Title

Quantification of Bacterial DNA in Septic Intensive Care Patients in Relation to Concentration of Antibiotics and Clinical Outcome: A Prospective Observation Study

Sponsor

Region Örebro County

Status

UNKNOWN

Phase

Observational Study

Condition raw

Septic Shock, Sepsis Bacterial, Sepsis

Condition normalized

Septic Shock, Sepsis Bacterial, Sepsis

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

Bacterial DNA clearance measured with droplet digital Polymerase Chain Reaction (ddPCR) as a biomarker for bacterial load in septic patients.

Target normalized

Bacterial DNA clearance measured with droplet digital Polymerase Chain Reaction (ddPCR) as a biomarker for bacterial load in septic patients.

Interventions

Blood sampling

Public preview

Source record

This study, sponsored by Region Örebro County, aims to establish ddPCR as a diagnostic tool for assessing bacterial load and treatment efficacy in septic patients. Given the high mortality rates associated with sepsis and the challenges in timely diagnosis and treatment, successful validation of this method could address significant unmet medical needs in critical care. The findings may enhance antibiotic stewardship and reduce the incidence of antibiotic resistance, positioning ddPCR as a valuable asset in the sepsis management market. The potential for commercialization hinges on demonstrating clinical utility and integration into existing diagnostic workflows, which could attract interest from diagnostic companies and pharmaceutical partners.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account

Create a free account first, then unlock a single report, buy credits or subscribe.